

# WFS1 R703C — Wolframin

Arginine → Cysteine at position 703 in luminal domain. ClinVar Conflicting including Cataract 41 + Wolfram + DFNA6. AlphaMissense 0.471 (below threshold),  $\Delta\Delta G$  +0.02. AM under-call with multi-phenotype.

## IDENTITY

Variant	R703C (p.Arginine703Cysteine)
DNA change	c.2107C>T
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV001299576
Amino acid change	Arginine (R) → Cysteine (C) — charge loss + thiol introduction.

## STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 703	<b>89.44</b> HIGH CONFIDENCE
Domain	C-terminal luminal domain (653-869)
Position context	C-terminal luminal domain · position 703 (pLDDT 89).
IDR flag	No — pLDDT well above 50 threshold

Position 703 in luminal domain near R708 region. Neighbors: PHE704 (2.4 Å — partner of V707F), GLY702 (2.5 Å — G702S!), SER821 (3.4 Å — long-range), GLY780 (3.6 Å — near V779/D801 region). R703C sits in the dense 702-708 cluster (with G702S, F704, V707F, R708L, R708C). Loss of R703 charge + thiol introduction.  $\Delta\Delta G$  essentially neutral; AM 0.471 below threshold; multi-phenotype confirms pathogenicity.

## COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

**0.471**am\_class: **Amb** —  
threshold > 0.564DYNAMUT2  $\Delta\Delta G$ **0.02** kcal/molStabilising · Job  
177992470845

PLDDT (ALPHAFOLD)

**89.44**

high confidence

## CLINICAL EVIDENCE

ClinVar classification

### CONFLICTING CLASSIFICATIONS OF PATHOGENICITY

Review status

criteria provided, conflicting classifications

Last evaluated

2025/12/15 00:00

Inheritance

Multi-phenotype AD.

WFS1 variant landscape

R703C is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)

- Cataract 41
- Wolfram syndrome 1
- Autosomal dominant nonsyndromic hearing loss 6 (DFNA6)

## RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$  + binding site affected → CATEGORY 3 – docking experiments  $\Delta\Delta G$  2–4 → CATEGORY 2 – pharmacological chaperones  $\Delta\Delta G > 4$  → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

**Category 4 — Stable Fold, Function Disrupted (AM under-call).**  $\Delta\Delta G \approx 0$ . AlphaMissense 0.471 below threshold but three documented phenotypes confirm pathogenicity.

Mechanism: charge loss + thiol in the dense 702-708 cluster. Therapeutic: same multi-variant cluster.

R703C extends the 702-708 multi-variant cluster — six Atlas variants now converge here.